GE'S Perception of Convergence

Although much smaller in scale, General Electric Co.'s $9.4 billion acquisition of Amersham PLC (now GE Healthcare's division GE Healthcare Bio-Sciences Inc.) [W#200310167] early last year is every bit as radical in its space as Johnson & Johnson's $25.4 billion acquisition of Guidant Corp. is in the cardiovascular world. [W# 200410276] And while J&J's move highlights the decades-long consolidation movement in major medical device sectors, GE's actions illustrate another key trend: convergence. The Amersham purchase puts GE for first time in the life sciences industry and has a systems-oriented, engineering company talking about intangible, biology-focused strategies like personalized medicine.

Although much smaller in scale, General Electric Co. 's $9.4 billion acquisition of Amersham PLC [See Deal] early last year is every bit as radical in its space as Johnson & Johnson 's $25.4 billion acquisition of Guidant Corp. is in the cardiovascular world. [See Deal] And while J&J's move highlights the decades-long consolidation movement in major medical device sectors, GE's actions illustrate another key trend: convergence. The Amersham purchase--now GE Healthcare 's division GE Healthcare Bio-Sciences Inc. --puts the imaging giant for first time in the life sciences industry and has a systems-oriented, engineering company talking about intangible, biology-focused strategies like personalized medicine.

Many analysts dismiss GE's emphasis on personalized medicine, noting that it is a concept, not a business. (See "GE's Personalized...

More from Archive

More from In Vivo

EU Medtech Outlook: The View From MedTech Europe Experts

 
• By Ashley Yeo

MedTech Forum 2025 was less MDR-focused than in previous years, as macro issues and exogenous threats were forced further into the center of medtech business thinking.

‘Confident In Lorundrostat’s Promise’: Mineralys CEO Talks Trials And Next Steps

 
• By Sushmita Panda

In a conversation with In Vivo, CEO Jon Congleton discusses Mineralys’s data-rich journey toward an NDA filing, the significance of recent trial wins and how its candidate may offer a dual benefit in blood pressure and renal protection.

BioBytes: Qubit Pharmaceuticals Unveils Quantum AI Model For Drug Discovery

 
• By David Wild

Qubit Pharmaceuticals and Sorbonne University launched a quantum AI model that could slash drug synthesis requirements and enable exploration of previously undruggable targets.